Experienced in Alveolar Soft Part Sarcoma

Dr. Sana D. Karam

Radiation Oncology
Washington University
4921 Parkview Pl, Lowr Lvl, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
16 Years of Experience
Experienced in Alveolar Soft Part Sarcoma
Washington University
4921 Parkview Pl, Lowr Lvl, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sana Karam is a Radiation Oncologist in Saint Louis, Missouri. Dr. Karam has been practicing medicine for over 16 years and is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, Laryngeal Cancer, Oral Squamous Cell Carcinoma, and Pancreatectomy. Dr. Karam is currently accepting new patients.

Her clinical research consists of co-authoring 166 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Radiation Oncology
Licenses
Radiology in MO
Hospital Affiliations
Barnes Jewish Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Sky Community Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER COMMERCIAL
View 3 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
4921 Parkview Pl, Lowr Lvl, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Phase I/Ib Trial of Radiotherapy in Combination With Durvalumab (MEDI4736) Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Phase I/Ib Trial of Radiotherapy in Combination With Durvalumab (MEDI4736) Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Enrollment Status: Completed
Publish Date: June 27, 2025
Intervention Type: Radiation, Drug, Procedure
Study Drug: Durvalumab
Study Phase: Phase 1
A Phase I/Ib Study of sEphB4-HSA in Combination With Chemotherapy or Cetuximab and Radiation Therapy in Patients With Intermediate to High Risk, Locally-Advanced Squamous Cell Carcinomas of the Head and Neck
A Phase I/Ib Study of sEphB4-HSA in Combination With Chemotherapy or Cetuximab and Radiation Therapy in Patients With Intermediate to High Risk, Locally-Advanced Squamous Cell Carcinomas of the Head and Neck
Enrollment Status: Completed
Publish Date: February 24, 2025
Intervention Type: Drug, Radiation
Study Drugs: sEphB4-HAS, Cisplatin, Carboplatin, Cetuximab
Study Phase: Phase 1
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase I/II Trial of Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV-unrelated Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Phase I/II Trial of Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV-unrelated Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 1
Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Enrollment Status: Withdrawn
Publish Date: December 06, 2022
Intervention Type: Drug, Radiation
Study Drugs: Nab-paclitaxel, Paclitaxel, Pembrolizumab
Study Phase: Phase 2
An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients With Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment
An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients With Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment
Enrollment Status: Completed
Publish Date: May 28, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

162 Total Publications

Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference.
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference.
Journal: Oncoimmunology
Published: December 19, 2024
Similar Doctors
Advanced in Alveolar Soft Part Sarcoma
Dr. Imran Zoberi
Radiation Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Imran Zoberi
Radiation Oncology

Washington University

4921 Parkview Pl, Lowr Lvl, 
Saint Louis, MO 
 (0.1 miles away)
314-362-9715
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Imran Zoberi is a Radiation Oncologist in Saint Louis, Missouri. Dr. Zoberi is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Breast Cancer, Angiosarcoma, Adult Soft Tissue Sarcoma, and Undifferentiated Pleomorphic Sarcoma. Dr. Zoberi is currently accepting new patients.

Advanced in Alveolar Soft Part Sarcoma
Dr. Stephanie M. Perkins
Radiation Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Stephanie M. Perkins
Radiation Oncology

Washington University

4921 Parkview Pl, Lowr Lvl, 
Saint Louis, MO 
 (0.1 miles away)
314-362-9715
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stephanie Perkins is a Radiation Oncologist in Saint Louis, Missouri. Dr. Perkins is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Posterior Fossa Tumor, Trigeminal Neuralgia, Adult Soft Tissue Sarcoma, and Neuralgia. Dr. Perkins is currently accepting new patients.

Advanced in Alveolar Soft Part Sarcoma
Dr. Robert C. Frazier
Radiation Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Robert C. Frazier
Radiation Oncology

West County Radiological Group Inc

901 Patients 1st Dr, 
Washington, MO 
 (40.5 miles away)
636-231-6252
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Frazier is a Radiation Oncologist in Washington, Missouri. Dr. Frazier is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Familial Prostate Cancer, Laryngeal Cancer, Plasmacytoma, and Adenoid Cystic Carcinoma. Dr. Frazier is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Karam's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 50 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile